Fda approves prophylactic treatment with vonvendi® [von willebrand factor (recombinant)] for adult patients living with severe type 3 von willebrand disease (vwd)

Cambridge, mass.--(business wire)--takeda pharmaceutical company limited (tse:4502/nyse:tak) (“takeda”) today announced that the u.s. food & drug administration (fda) approved vonvendi® [von willebrand factor (recombinant)] for routine prophylaxis to reduce the frequency of bleeding episodes in patients with severe type 3 von willebrand disease (vwd) receiving on-demand therapy. vonvendi is the only recombinant von willebrand factor (vwf) replacement therapy, and the first and only treatmen
TAK Ratings Summary
TAK Quant Ranking